Results 41 to 50 of about 10,900 (261)

Model evaluation of target product profiles of an infant vaccine against respiratory syncytial virus (RSV) in a developed country setting [PDF]

, 2020
Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in children worldwide and is a significant cause of hospital admissions in young children in England.
Kinyanjui, Timothy, Nokes, D. James, Pan-Ngum, Wirichada, Saralamba, Sompob, Taylor, Sylvia, White, Lisa J.   +5 more
core   +1 more source

Effectiveness and Safety of Palivizumab for the Prevention of Serious Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus: A Systematic Review

American Journal of Perinatology, 2022
Objective  Palivizumab is a humanized monoclonal antibody approved for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV) in infants and young children at high risk of RSV disease.
Tara Gonzales, A. Bergamasco, T. Cristarella, Camille Goyer, M. Wojdyla, Abiola Oladapo, John Sawicky, J. Yee, Y. Moride   +8 more
semanticscholar   +1 more source

Summary of the National Advisory Committee on Immunization (NACI) statement update on the recommended use of palivizumab to reduce complications of respiratory syncytial virus infection in infants

Canada communicable disease report = Releve des maladies transmissibles au Canada, 2022
Background Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in young children worldwide. Underlying health conditions, especially premature birth, chronic lung disease and congenital heart disease ...
D. Moore, A. Sinilaité, A. Killikelly
semanticscholar   +1 more source

Prophylaxis protects infants with congenital heart disease from severe forms of RSV infection: an Italian observational retrospective study

Italian Journal of Pediatrics, 2023
Background In children with congenital heart disease (CHD) respiratory syncytial virus (RSV) infection may have a severe course, with increased risk of morbidity and mortality, requiring hospital admission and intensive care. The aim of the present study
Chiara Ratti, Anna della Greca, Deborah Bertoncelli, Monica Rubini, Bertrand Tchana   +4 more
doaj   +1 more source

Respiratory syncytial virus: Clinical and epidemiological pattern in pediatric patients admitted to a children’s hospital between 2000 and 2013 [PDF]

, 2014
INTRODUCTION: Respiratory syncytial virus (RSV) is the major causative organism associated with acute lower respiratory tract infections in children.The objective of this study was to describe the clinical and epidemiological pattern of RSV and identify ...
Bakir, Julia, Castellano, Verónica, Gentile, Ángela, Grobaporto, Marcela, Juárez, María del Valle, Lucion, María Florencia, Mistchenko, Alicia Susana, Romanin, Viviana Sandra, Viegas, Mariana   +8 more
core   +1 more source

RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020

Human Vaccines & Immunotherapeutics, 2022
Respiratory syncytial virus (RSV) is a leading cause of bronchiolitis and pneumonia in children under one year and a leading cause of infant hospitalization.
E. Packnett, I. Winer, H. Larkin, Abiola Oladapo, T. Gonzalez, M. Wojdyla, M. Goldstein, V. Smith   +7 more
semanticscholar   +1 more source

Epidemiology and potential preventative measures for viral infections in children with malignancy and those undergoing hematopoietic cell transplantation. [PDF]

, 2012
In pediatric patients with malignancy and those receiving hematopoietic stem cell transplants, bacterial and fungal infections have been the focus of fever and neutropenia episodes for decades.
Alexander, Sarah, Dvorak, Christopher C, Fisher, Brian T, Sung, Lillian, Zaoutis, Theoklis E, Zerr, Danielle M   +5 more
core   +1 more source

Target Trial Emulation and Bias Through Missing Eligibility Data: An Application to a Study of Palivizumab for the Prevention of Hospitalization Due to Infant Respiratory Illness

American Journal of Epidemiology, 2022
Target trial emulation (TTE) applies the principles of randomized controlled trials to the causal analysis of observational data sets. One challenge that is rarely considered in TTE is the sources of bias that may arise if the variables involved in the ...
Daniel Tompsett, A. Zylbersztejn, P. Hardelid, B. D. De Stavola   +3 more
semanticscholar   +1 more source

Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. [PDF]

, 2015
HIV-1 mucosal transmission begins with virus or virus-infected cells moving through mucus across mucosal epithelium to infect CD4+ T cells. Although broadly neutralizing antibodies (bnAbs) are the type of HIV-1 antibodies that are most likely protective,
Alam, SM, Blair, L, Chao, A, Cocklin, SL, Dennison, SM, Duffy, R, Evans, A, Ferrari, G, Forthal, DN, Gao, F, Giorgi, EE, Haynes, BF, Kaewkungwal, J, Kim, JH, Klein, K, Korber, BT, Kumar, A, Landucci, G, Letvin, NL, Li, H, Liao, HX, Liu, P, Michael, NL, Montefiori, DC, Moody, MA, Moog, C, Nicely, NI, Nitayaphan, S, Pemble Iv, CW, Pitisuttithum, P, Pollara, J, Rerks-Ngarm, S, Robb, ML, Robinson, J, Santra, S, Schmitz, JE, Schutte, RJ, Shattock, RJ, Shaw, GM, Shen, X, Soderberg, KA, Tomaras, GD, Vidnovic, K, Warrier, R, Xia, SM, Zhang, R   +45 more
core   +1 more source

Risk Factors of Very Severe RSV Infections in a Multicenter Cohort of Very Preterm and Extreme Preterm Babies Receiving or Not Palivizumab

Frontiers in Pediatrics, 2022
Introduction Preterm infants are at risk of lower respiratory tract infections (LRTI), including Respiratory Syncytial Virus (RSV) associated bronchiolitis, for which palivizumab prophylaxis can be proposed.
Gwenaelle Mulot, M. Benchaib, F. Plaisant, D. Ploin, Y. Gillet, E. Javouhey, O. Claris, J. Picaud, J. Casalegno, M. Butin   +9 more
semanticscholar   +1 more source